©2024 Stanford Medicine
Study in Subjects With Small Primary Choroidal Melanoma
Not Recruiting
Trial ID: NCT03052127
Purpose
The primary objective is to assess the safety, immunogenicity and efficacy of one of three
dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser
applications for the treatment of subjects with primary choroidal melanoma.
Official Title
A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma
Stanford Investigator(s)
Prithvi Mruthyunjaya, MD, MHS
Professor of Ophthalmology and, by courtesy, of Radiation Oncology
Eligibility
Inclusion Criteria:
- Diagnosis of choroidal melanoma
Exclusion Criteria:
- Have known contraindications or sensitivities to the study drug
Intervention(s):
drug: Light-activated AU-011
device: Laser Activation
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mariana Nunez
650-497-7846